Drug Trial Radar · NCT00756028
Short Versus Long Protocol for IVF and IVF+ICSI
Last checked: Nov 20, 2026Latest source record: Jan 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,099
Actual
Start
Jan 2009
Primary completion
Dec 2014
Study completion Dec 2015
Sponsor
- Lead sponsor
- Peter Hornnes, MD, DMScAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 19, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 39 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Purpose: Comparing a GnRH agonist and an antagonist protocol for IVF/ICSI with regard to 1. frequency of ovarian hyperstimulation syndrome (OHSS) (1. outcome measure) 2. quality of life (2. outcome measure) 3. live birth rate (2. outcome measure) 4. gene expression profiles of granulosa and cumulus cells, and concentrations of estradiol and vascular endothelial growth factor in follicular fluid(not only compared between GnRH agonist and antagonist protocol, but also between patients with OHSS and no OHSS and patients becoming pregnant and not becoming pregnant (2. outcome measure), and 5. number of oocytes removed per treatment, number of embryo transfers per treatment and number of spontaneous abortions per treatment (these three parameters are tertiary outcome measures). In addition to the above mentioned efficacy outcome measures the safety outcome measure "frequency of known side-effects" will be compared between the two protocols.
Conditions
- Infertility
- Ovarian Hyperstimulation Syndrome
- Quality of Life
- Live Birth
Interventions
Patients receiving short protocol IVF/ICSI-treatment.Drug
Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day
Long protocolDrug
Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Ovarian Hyperstimulation Syndrome (OHSS)Time frame: 3 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Dronninglund Fertility Clinic
Dronninglund, Denmark
Fertility Clinic, Hvidovre Hospital
Hvidovre, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.